corp_html/news/20.html

<p align="center"><b>PLIVA Facilities Pass Food and Drug Administration (FDA) 
  Inspection</b></p>
<p>Zagreb, 27th October 1999</p>
<p>PLIVAs new Azithromycin facility was found to be in compliance with good manufacturing 
  practice according to the Food and Drug Administration (FDA) inspection carried 
  out in mid-October of 1999. </p>
<p>Azithromycin is PLIVAs leading product and is exclusively supplied to Pfizer 
  according to a licensing agreement. This was the first inspection by the FDA 
  of the new Azithromycin facility in Savski Marof, which was completed at the 
  end of 1998. Upon receipt of FDA approval of the changes to the Azithromycin 
  NDA (New drug application) submitted by Pfizer, PLIVA will be in a position 
  to commence shipments of Azithromycin produced in the new facility to the United 
  States. The new facility has the capacity to meet all PLIVA and Pfizers forecasted 
  demands for Azithromycin.</p>
<p>The FDA also carried out inspections of other PLIVA facilities involved in 
  the production of a range of active pharmaceutical ingredients for sale on the 
  US market. Authorisation to begin or resume usage of active pharmaceutical ingredients 
  produced in the facilities that were subject to this routine inspection should 
  be given to customers by the FDA shortly.</p>
1	<p align="center"><b>PLIVA Facilities Pass Food and Drug Administration (FDA)
2	Inspection</b></p>
3	<p>Zagreb, 27th October 1999</p>
4	<p>PLIVAs new Azithromycin facility was found to be in compliance with good manufacturing
5	practice according to the Food and Drug Administration (FDA) inspection carried
6	out in mid-October of 1999. </p>
7	<p>Azithromycin is PLIVAs leading product and is exclusively supplied to Pfizer
8	according to a licensing agreement. This was the first inspection by the FDA
9	of the new Azithromycin facility in Savski Marof, which was completed at the
10	end of 1998. Upon receipt of FDA approval of the changes to the Azithromycin
11	NDA (New drug application) submitted by Pfizer, PLIVA will be in a position
12	to commence shipments of Azithromycin produced in the new facility to the United
13	States. The new facility has the capacity to meet all PLIVA and Pfizers forecasted
14	demands for Azithromycin.</p>
15	<p>The FDA also carried out inspections of other PLIVA facilities involved in
16	the production of a range of active pharmaceutical ingredients for sale on the
17	US market. Authorisation to begin or resume usage of active pharmaceutical ingredients
18	produced in the facilities that were subject to this routine inspection should
19	be given to customers by the FDA shortly.</p>